<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="HAF6C444EEBFE47E1A3A12C8A60B2C592" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 3884 RH: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-08-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code><calendar display="yes">Union Calendar No. 132</calendar><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3884</legis-num><associated-doc role="report" display="yes">[Report No. 118–166]</associated-doc><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230607">June 7, 2023</action-date><action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> (for himself, <cosponsor name-id="D000096">Mr. Davis of Illinois</cosponsor>, and <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><action display="yes"><action-date date="20230825">August 25, 2023</action-date><action-desc>Additional sponsor: <cosponsor name-id="L000551">Ms. Lee of California</cosponsor></action-desc></action><action display="yes"><action-date date="20230825">August 25, 2023</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc><action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction><action-instruction>For text of introduced bill, see copy of bill as introduced on June 7, 2023</action-instruction></action><action><action-desc><pagebreak></pagebreak></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.<pagebreak></pagebreak></official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H2C8B4DAD642149FDBFDCD4742B87AF0B"><section id="H724E8214B4364F63BF469B63268E727A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</short-title></quote>.</text></section><section id="H0B097735AC7540C7A5D40D3F8FCB0CF7"><enum>2.</enum><header>Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment</header><text display-inline="no-display-inline">Section 1106(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300b-5">42 U.S.C. 300b–5(b)</external-xref>) is amended—</text><paragraph id="H35C3820D59E34893AD660C64C9AD8E7B"><enum>(1)</enum><text>in paragraph (3)(A), by inserting <quote>, grant, or cooperative agreement</quote> after <quote>contract</quote>; and </text></paragraph><paragraph id="HD6D4269D4BBC49658F7D0B4CD76FAE03"><enum>(2)</enum><text>in paragraph (6), by striking <quote>$4,455,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$8,205,000 for each of fiscal years 2024 through 2028</quote>.</text></paragraph></section></legis-body><endorsement display="yes"><action-date date="20230825">August 25, 2023</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc></endorsement></bill> 

